Partnering with ProteoDesign
Partnering has been at our core since the company’s inception. Our strategy has enabled ProteoDesign to further validate our SEPL platform for the development of next-generation therapeutics in several areas with top tier collaborators from the academy and the industry.
Our aim is to continue pursuing and building such long-term relationships with both academic and industrial partners interested in developing the next-generation of biologics. You can contact Gerard, our Director of Business Development, for such purpose: email@example.com
Fc-synthetic peptide conjugates
To extend the half-life of synthetic peptide.
Frutos S., Org. Biomol. Chem. 2016.
To optimize therapeutic properties.
Single domain antibody conjugates
To deliver cargoes conjugated to sdAb.
To boost innate immunity.
Barbuto S., Nat. Chem. Biol. 2013.
To enable personalized therapeutics.